CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
• A. O. Smith CEO Stephen Shafer named chairman